Pieris Pharmaceuticals Inc (PIRS)

$10.97 0.28 (2.49%)

15:57 EDT PIRS Stock Quote Delayed 30 Minutes

PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024

By InvestorPlace Earnings May 17, 2024

Pieris Pharmaceuticals just reported results for the first quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

3 Doomed Biotech Stocks Destined for Disaster

More Articles

Volume:

Previous Close -

Market Cap 1.09B

PE Ratio 219.40

EPS 0.05

Volume (Avg. Vol.) 5,735

Day's Range $10.97 - $11.54

52-Week Range $0.14 - $12.93

Dividend & Yield N/A (N/A)

PIRS Stock Predictions, Articles, and Pieris Pharmaceuticals Inc News

From InvestorPlace
From the Web

7 Penny Stocks to Buy to Sidestep the Noise on Wall Street

By Josh Enomoto, InvestorPlace Contributor Oct 21, 2021

With so much chaos occurring on Wall Street, these lesser-known penny stocks to buy might fly profitably under the radar.

PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today

By William White, InvestorPlace Writer May 26, 2021

Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer May 26, 2021

Good morning, investors! Join us as we kick off the day with a look at the biggest pre-market stock movers for Wednesday.

5 Big Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor Mar 20, 2018

Small biotech stocks can pack a wallop. Here are five biotech stocks that have prospects bigger than their share prices.

4 Stocks Under $3 Insiders Are Aggressively Buying

From Benzinga May 17, 2022

US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

From Benzinga May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Recap: Pieris Pharmaceuticals Q1 Earnings

From Benzinga May 11, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Pieris Pharmaceuticals's Earnings Outlook

From Benzinga May 10, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Pieris Pharmaceuticals will report an earnings per share (EPS) of $-0.11.

Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed

From Benzinga Mar 4, 2022

According to Benzinga Pro data, during Q4, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $8.44 million. Earnings were up 42.36%, but Pieris Pharmaceuticals still reported...

Recap: Pieris Pharmaceuticals Q4 Earnings

From Benzinga Mar 1, 2022

Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

ADVERTISEMENT